Jason Cross

This inventor holds 29 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Heterocyclic Inhibitors. Top assignees: The University of Texas System, Chempartner Corporation, Navire Pharma, Inc.. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jason Cross. Retrieved from https://idiyas.com/inventor/jason-cross

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 8)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 10)

EPO Patents = 8 (Patent Applications = 17)

Average Co-Inventor Count = 6.2

ph-index = 5

Forward Citations = 71(Granted Patents)

Company Filing History:

25 out of 5,640

The University of Texas System

patents

6 out of 7

Chempartner Corporation

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

Areas of Expertise:

Imidazopiperazine

PTPN11

Transcription Activating Proteins

Heterocyclic

Kinase Inhibitors

DLK Kinase

ATR Kinase

Indoleamine

Tryptophan Dioxygenase

Bicyclo[1.1.1]pentane

Substituted Heterocyclic

Tetrahydropyrido

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12559497 - Imidazopiperazine inhibitors of transcription activating proteins (2026-02-24),

2. 12540139 - Imidazopiperazine inhibitors of transcription activating proteins (2026-02-03),

3. 12286406 - Inhibitors of receptor interacting protein kinase I for the treatment of disease (2025-04-29),

4. 12186324 - Imidazopiperazine inhibitors of transcription activating proteins (2025-01-07),

5. 11945815 - PTPN11 inhibitors (2024-04-02),

6. 11932643 - Substituted heterocyclic inhibitors of PTPN11 (2024-03-19),

7. 11840536 - Heterocyclic inhibitors of PTPN11 (2023-12-12),

8. 11753381 - Inhibitors of receptor interacting protein kinase I for the treatment of disease (2023-09-12),

9. 11718612 - Inhibitors of receptor interacting protein kinase I for the treatment of disease (2023-08-08),

10. 11690850 - Inhibitors of receptor interacting protein kinase I for the treatment of disease (2023-07-04),

11. 11560366 - Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease (2023-01-24),

12. 11466017 - Heterocyclic inhibitors of PTPN11 (2022-10-11),

13. 11434233 - Heterocyclic inhibitors of ATR kinase (2022-09-06),

14. 11365189 - Heterocyclic inhibitors of tyrosine kinase (2022-06-21),

15. 11173145 - Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase (2021-11-16),

Title: Jason Cross - Innovative Inventor from Pearland, TX

Introduction: Jason Cross is a talented inventor based in Pearland, Texas, known for his groundbreaking contributions to various industries.

Latest Patents: Jason Cross holds several patents in the fields of technology, healthcare, and consumer products, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Jason Cross has consistently demonstrated his ability to transform creative concepts into tangible inventions that have made a significant impact in the market.

Collaborations: Throughout his career, Jason Cross has collaborated with leading companies, research institutions, and universities to further develop and commercialize his inventions, solidifying his reputation as a sought-after innovator.

Conclusion: Jason Cross continues to push the boundaries of innovation, and his passion for creating solutions to real-world problems sets him apart as a visionary inventor in the industry.

Profile summary based on public USPTO records.